burn treatment
first responders and civilian victims
NeoMatrix Therapeutics is a clinical-stage company committed to developing bioactive peptides that prevent injury progression thereby rescuing tissue and speeding healing.
​
Our lead candidates focus on the treatment of severe burns and have shown the potential to significantly improve the quality of life and clinical outcomes of patients. By limiting injury progression following the initial burn, healing time is shortened and scarring can be reduced.
Continued tissue destruction following an initial burn injury is a challenging phenomenon. Our novel peptides have indicated a capacity for use under a variety of conditions besides burns.
INNOVATIONS IN HEALING
Reimagining Tissue Injury Therapies
Neomatrix Therapeutics currently has two bioactive peptides in development. Right now, NMT-cP12 is engaged in a Phase 2a clinical trial. The company’s other peptide, NMT-cNP8 recently completed a Phase 1 clinical trial. Furthermore, Neomatrix is exploring cNP8 topical therapy for battlefield conditions as well as civilian settings.
These innovative peptides have shown tremendous potential to transform the treatment of severe burns and tissue injury.